Search
Careers
Contact us
Menu
Careers
Contact us
ABOUT INOTREM
COMPANY OVERVIEW
LEADERSHIP TEAM
BOARD OF DIRECTORS
ADVISORY BOARDS
THERAPEUTIC APPROACH
TREM-1 PATHWAY
PERSONALIZED MEDICINE
DRUG DEVELOPMENT
NANGIBOTIDE AND MONOCLONAL ANTIBODIES
PIPELINE
THERAPEUTIC AREAS
INVESTORS
NEWS
PRESS RELEASES
EVENTS
SCIENTIFIC PUBLICATIONS
Menu
ABOUT INOTREM
COMPANY OVERVIEW
LEADERSHIP TEAM
BOARD OF DIRECTORS
ADVISORY BOARDS
THERAPEUTIC APPROACH
TREM-1 PATHWAY
PERSONALIZED MEDICINE
DRUG DEVELOPMENT
NANGIBOTIDE AND MONOCLONAL ANTIBODIES
PIPELINE
THERAPEUTIC AREAS
INVESTORS
NEWS
PRESS RELEASES
EVENTS
SCIENTIFIC PUBLICATIONS
ABOUT INOTREM
COMPANY OVERVIEW
LEADERSHIP TEAM
BOARD OF DIRECTORS
ADVISORY BOARDS
THERAPEUTIC APPROACH
TREM-1 PATHWAY
PERSONALIZED MEDICINE
DRUG DEVELOPMENT
NANGIBOTIDE AND MONOCLONAL ANTIBODIES
PIPELINE
THERAPEUTIC AREAS
INVESTORS
NEWS
PRESS RELEASES
EVENTS
SCIENTIFIC PUBLICATIONS
CAREERS
CONTACT US
Menu
ABOUT INOTREM
COMPANY OVERVIEW
LEADERSHIP TEAM
BOARD OF DIRECTORS
ADVISORY BOARDS
THERAPEUTIC APPROACH
TREM-1 PATHWAY
PERSONALIZED MEDICINE
DRUG DEVELOPMENT
NANGIBOTIDE AND MONOCLONAL ANTIBODIES
PIPELINE
THERAPEUTIC AREAS
INVESTORS
NEWS
PRESS RELEASES
EVENTS
SCIENTIFIC PUBLICATIONS
CAREERS
CONTACT US
Investors
A novel approach to target inflammatory diseases
Inotrem is supported by top-tier international investors.